Abstracts tagged "Interleukins"

Abstract Number: 1324 • ACR Convergence 2023
Previous History of Serious Infection Is Associated with the Use of IL-6 Inhibitors in Rheumatoid Arthritis in Wales, UK
Roxanne Cooksey¹ and Ernest Choy², ¹Cardiff University, Cardiff, United Kingdom, ²Section of Rheumatology, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Biologic therapy has revolutionised the treatment of rheumatoid arthritis (RA). Randomised control trials have shown that IL-6 inhibitors are superior to adalimumab, a TNF…
Abstract Number: 2475 • ACR Convergence 2023
Elevation of the IL-17 Cytokine Family Distinguishes Kawasaki Disease from Other Pediatric Inflammatory Disorders
Kailey Brodeur¹, Meng Liu², Yan Du³, Lauren Henderson¹, Joyce Chang¹, Jane Newburger¹, Peter Nigrovic¹ and Pui Lee⁴, ¹Boston Children's Hospital, Boston, MA, ²Southern Medical University, Boston, MA, ³Harvard medical school, Boston, MA, ⁴Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Kawasaki disease (KD) is a systemic vasculitis of young children that can lead to the development of coronary artery aneurysms (CAA) in up to…
Abstract Number: 1422 • ACR Convergence 2023
Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: Integrated Analysis of Psoriasis and Psoriatic Arthritis Clinical Trial Data
Kenneth Gordon¹, Andrew Blauvelt², Herve Bachelez³, Laura Coates⁴, Blair Kaplan⁵, Willem Koetse⁵, Leonidas Drogaris⁵, Ranjeeta Sinvhal⁵ and Kim A Papp⁶, ¹Medical College of Wisconsin, Milwaukee, WI, ²Oregon Medical Research Center, Portland, OR, ³APHP Hopital Saint-Louis, Universite de Paris, Paris, France, ⁴University of Oxford, Oxford, United Kingdom, ⁵AbbVie, Inc., North Chicago, IL, ⁶Alliance Clinical Research and Probity Medical Research, Waterloo, and University of Toronto, Toronto, ON, Canada
Background/Purpose: Risankizumab, an interleukin-23 inhibitor, was efficacious and well tolerated in plaque psoriasis (PsO) and psoriatic arthritis (PsA) clinical trials.The objective of this integrated data…
Abstract Number: 2504 • ACR Convergence 2023
The Effect of Inflammatory Conditions on the Regulation of Canonical and Non-canonical NF-kB Pathways via Bcl11b
Sara Parsa¹, Saeid Rahmani², Nadine Davelaar¹, Adriana M.C.mus¹ and Erik Lubberts¹, ¹Erasmus Medical Center, Rotterdam, Netherlands, ²Institute for Research in Fundamental Sciences, Tehran, Iran
Background/Purpose: Bcl11b, a zinc finger bi-functional transcription factor, is highly expressed in various tissues during development and differentiation, including stromal cells. It has been shown…
Abstract Number: 1428 • ACR Convergence 2023
Guselkumab Provides Clinically Meaningful Improvents in Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Who Are Inadequate Responders to Tumour Necrosis Factor Inhibitors: Results Through One Year of a Phase 3b, Randomized, Controlled Study (COSMOS)
Laure Gossec¹, Xenofon Baraliakos², James Galloway³, Lars Erik⁴, Vilija Oke⁵, Petros Sfikakis⁶, Emmanouil Rampakakis⁷, Mohamed Sharaf⁸, Frederic Lavie⁹ and Iain McInnes¹⁰, ¹Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³King's College London, London, United Kingdom, ⁴Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶National Kapodistrian University of Athens Medical School, Athens, Greece, ⁷JSS Medical Research, Saint-Laurent, QC, Canada, ⁸Immunology, Janssen MEA, Dubai, United Arab Emirates, ⁹The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ¹⁰University of Glasgow, Glasgow, United Kingdom
Background/Purpose: In the Phase 3b COSMOS trial, guselkumab (GUS), a fully human IL-23p19 inhibitor (i), was associated with significantly greater improvements vs placebo (PBO) in…
Abstract Number: 2505 • ACR Convergence 2023
Discovery of First-in-Class IRAK4 Scaffolding Inhibitors for the Treatment of Inflammatory Disorders
Kate Byth¹, Rodney Morgan², Pierre Michelys³, Kellie Demock², Geetha Kannan², Qing Chen¹, Brian Sanchez², Xiaokang Lu², Alissa Telling², Chuck Lesch², Carmen Yu², Sarah Bradley², Brian Andresen¹, Sherif Hassanien², Clarke Taylor², Zhilin Hou², Ken Borrelli¹, Anna Gardberg¹, Erika Munschy¹, Adam Schwaid¹, Anthony Opipari², Shifeng Pan³ and Luigi Franchi², ¹Odyssey Therapeutics, Boston, MA, ²Odyssey Therapeutics, Ann Arbor, MI, ³Odyssey Therapeutics, San Diego, CA
Background/Purpose: Interleukin-1 receptor-associated kinase 4 (IRAK4), is a key node that mediates inflammatory signaling in response to activation of toll-like receptor (TLR) and IL-1 receptor…
Abstract Number: 1434 • ACR Convergence 2023
Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 2 Trial
Andrew Östör¹, Filip Van den Bosch², Kim A Papp³, Cecilia Asnal⁴, Ricardo Blanco⁵, Jacob Aelion⁶, Vassilis Stakias⁷, Thomas Iyile⁷, Kyle Carter⁷, Ahmed Soliman⁷, Leonidas Drogaris⁷, Michael Chen⁷, Byron Padilla⁷ and Alan Kivitz⁸, ¹Monash University & Emeritus Research; Australian National University, Melbourne, Australia, ²Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ³Alliance Clinical Research and Probity Medical Research, Waterloo, and University of Toronto, Toronto, ON, Canada, ⁴Hospital Alemán, Buenos Aires, Argentina, ⁵Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁶West Tennessee Research Institute, Jackson, TN, ⁷AbbVie, Inc., North Chicago, IL, ⁸Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: PsA is a chronic systemic inflammatory disease that affects 30% of patients diagnosed with psoriasis, with a clinical burden that includes dactylitis, enthesitis, cutaneous…
Abstract Number: 2506 • ACR Convergence 2023
Role of TGF-β Activated Kinase 1 in Cytokine-Driven Juvenile Idiopathic Arthritis Synovial Fibroblasts Activation
Meena Afroze Shanta¹, Anil Singh², Paul Panipinto³ and Salahuddin Ahmed², ¹College of Pharmacy and Pharmaceutical Science, Washington State University, Spokane, WA, ²Washington State university, Spokane, WA, ³Washington State University College of Pharmaceutical Science and Molecular Medicine, Spokane, WA
Background/Purpose: Chronic synovitis is a debilitating manifestation of juvenile idiopathic arthritis (JIA). Synovial fibroblast is a major preparator of inflammatory arthritis and has not been…
Abstract Number: 1435 • ACR Convergence 2023
Long-Term Efficacy and Safety of Risankizumab for CsDMARD-IR Patients with Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 1 Trial
Lars Erik¹, Mauro Keiserman², Kim A Papp³, Leslie McCasland⁴, Douglas White⁵, Vassilis Stakias⁶, Thomas Iyile⁶, Kyle Carter⁶, Ahmed Soliman⁶, Leonidas Drogaris⁶, Michael Chen⁶, Byron Padilla⁶ and Frank Behrens⁷, ¹Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ²Pontifical Catholic University School of Medicine, Porto Alegre, Brazil, ³Alliance Clinical Research and Probity Medical Research, Waterloo, and University of Toronto, Toronto, ON, Canada, ⁴Arthritis and Rheumatism Associates, Jonesboro, AR, ⁵Waikato Clinical School, University of Auckland, Hamilton, New Zealand, ⁶AbbVie, Inc., North Chicago, IL, ⁷Goethe-University & Fraunhofer ITMP, Frankfurt, Germany
Background/Purpose: Risankizumab (RZB), a humanized immunoglobulin G1 monoclonal antibody that inhibits interleukin-23 by targeting its p19 subunit with high affinity and specificity, is approved for…
Abstract Number: 2508 • ACR Convergence 2023
Chronic IL-6 Trans-Signaling Enhances Stem Cell-Like Characteristics of Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh and Salahuddin Ahmed, Washington State university, Spokane, WA
Background/Purpose: Chronic exposure to IL-6 trans-signaling has been shown to significantly impact the characteristics of rheumatoid arthritis synovial fibroblasts (RASFs). Previous studies have demonstrated that…
Abstract Number: 113 • 2023 Pediatric Rheumatology Symposium
Proportion of Patients with a Polyphasic Disease Course in Systemic-onset Juvenile Idiopathic Arthritis May Be Higher in the Age of Cytokine Inhibitors
Itay Marmor¹, Rotem Semo Oz², Amir hendel³, Guy Hazan⁴, Kevin Baszis⁵, Anthony French⁵, Cuoghi Edens⁶, Irit Tirosh⁷, Yonatan Butbul Aviel⁸, Liora Harel⁹ and Gil Amarilyo¹⁰, ¹Dana-Dwek Children's Hospital, Hod Hasharon, Israel, ²Sheba medical center, Herzelyia, Israel, ³Tel Aviv University, Tel Aviv, Israel, ⁴Soroka University Medical Center, Be'er Sheva, Israel, ⁵Washington University School of Medicine, St Louis, MO, ⁶University of Chicago, Chicago, IL, ⁷Sheba Medical Center, Savyon, Israel, ⁸Rambam Medical center, Haifa, Israel, ⁹Scheiders Children Medical Center of Israel, Petah-Tiqva, Israel, ¹⁰Schneider Children's Medical Center of Israel, Petach Tikva, Israel
Background/Purpose: Systemic-onset juvenile idiopathic arthritis (sJIA) is a pediatric autoinflammatory condition, known for significant variability between patients in its severity and long-term outcomes. The classification…
Abstract Number: 0048 • ACR Convergence 2022
Combination of Repetitive Inhalant Endotoxin Exposure and Collagen-induced Arthritis Interact in a Testosterone-dependent Manner to Drive Inflammatory Lung Disease Processes and Arthritis Severity in Mice
Elizabeth Ramler¹, Ted Mikuls², Geoffrey Thiele³, Amy Nelson³, Michael Duryee³, Rohit Gaurav³, Todd Wyatt¹, Aaron Schwabb³, carlos hunter³, Bryant England³ and Jill Poole³, ¹University of Nebraska Medical Center, Omaha, ²Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Respiratory-related diseases are among the most common causes of death in rheumatoid arthritis (RA). Although autoimmune diseases are reported in higher frequency in females,…
Abstract Number: 1421 • ACR Convergence 2022
Pharmacokinetics, Safety, Tolerability, and Immunogenicity of a Proposed Tocilizumab Biosimilar (MSB11456) versus US‑licensed Tocilizumab: Results of a Randomized, Double-blind, Parallel‑group, Single‑intravenous Dose Study in Healthy Adults (APTURA II)
Monika Tomaszewska-Kiecana¹, Martin Ullmann², Emmanuelle Vincent², Corinne Petit-frere², Joëlle Monnet³ and Andras Illes², ¹Biokinetica S.A., Jozefow, Poland, ²Fresenius Kabi SwissBioSim, Eysins, Switzerland, ³Fresenius Kabi Swiss BioSim, Eysins, Switzerland
Background/Purpose: Tocilizumab is a biologic anti-interleukin-6 receptor monoclonal immunoglobin G1 antibody indicated for treating inflammatory diseases, including RA, and cytokine release syndrome. MSB11456 is a…
Abstract Number: 0403 • ACR Convergence 2022
Efficacy and Safety of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis: 16-Week Results from a Phase 3 Study
Yu Xue¹, Jiankang Hu², Dongzhou Liu³, Jingyang Li⁴, Huaxiang Wu⁵, Chunyu Tan⁶, Lie Dai⁷, Mengru Liu⁸, Hongying Li⁸ and Hejian Zou¹, ¹Huashan Hospital affiliated to Fudan University, Shanghai, China, ²Jiangxi Pingxiang People’s Hospital, Shanghai, China, ³Shenzhen People’s Hospital （The Second Clinical Medical College of Jinan University）, Shanghai, China, ⁴Zhuzhou Central Hospital, Shanghai, China, ⁵The Second Affiliated Hospital Zhejiang University School of Medicine, Shanghai, China, ⁶West China Hospital of Sichuan University, Shanghai, China, ⁷Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Shanghai, China, ⁸Eli Lilly and Company, Shanghai, China
Background/Purpose: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, has demonstrated efficacy in global clinical trials in patients with radiographic axial spondyloarthritis (r-axSpA)/ankylosing spondylitis…
Abstract Number: 1487 • ACR Convergence 2022
Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23
James Krueger¹, Kilian Eyerich², Dennis McGonagle³, Carrie Greving⁴, Kacey Sachen⁴, Deepa Hammaker⁴, Phuc Bao⁴, Eilyn Lacy⁴, M. Merle Elloso⁵, Yevgeniya Orlovsky⁵, Iain B McInnes⁶ and Anne Fourie⁷, ¹The Rockefeller University, New York, NY, ²Technical University, Munich, Germany / Karolinska Institute, Stockholm, Sweden, ³University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁴Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, ⁵Janssen Research and Development, LLC, Spring House, PA, ⁶Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁷Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, CA
Background/Purpose: Clinically relevant differences between therapeutic antibodies against the same target may relate to their unique molecular attributes. Differences in therapeutic profiles across the domains…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].